MIJ821 (onfasprodil) in healthy volunteers: First‐in‐human, randomized, placebo‐controlled study (single ascending dose and repeated intravenous dose)
Clinical and Translational Science · 2023-11 · 16 (11) · 2236-2252
DOI: 10.1111/cts.13623 ↗At a glance
Randomisierte kontrollierte Studie in Clinical and Translational Science, published online on 2023-10-10. Written by Baltazar Gomez-Mancilla and 15 co-authors. Institution: Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. Major MEDLINE topics: Infusions, Intravenous. Cited 12 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
This single‐center study administered MIJ821 (onfasprodil) as an intravenous infusion to healthy volunteers and included two parts: a single ascending dose study (Part 1) and a repeated intravenous dose study (Part 2). Primary objective was to evaluate the safety and tolerability of single ascending intravenous doses infused over a 40‐min period and of two repeated doses (1 week apart) of MIJ821 in healthy volunteers. Secondary objectives were to assess the pharmacokinetics of MIJ821 after intravenous infusion in Part 1 and Part 2 of the study. Overall, 43 subjects in Part 1 and 12 subjects in Part 2 were randomized in the study. Median age in Part 1 and Part 2 was 45.0 and 43.5 years, respectively, with the majority being Caucasian (Part 1: 84%; Part 2: 92%). 19 subjects (44.2%) in Part 1 and 8 subjects (66.7%) in Part 2 experienced at least one adverse event (AE). Following single dose in Part 1 and Part 2, the AUC inf values of MIJ821 increased in a dose‐proportional manner across the dose range 0.016–0.48 mg/kg and the C max values in a slight overproportional manner across the dose range 0.048–0.48 mg/kg. At the highest dose of 0.48 mg/kg, the geometric mean AUC inf was 708 h ng/mL and the geometric mean C max was 462 ng/mL. Inspection of 1‐h post‐dose resting electroencephalography activity across cohorts showed a relationship to administered dose, providing exploratory evidence of distal target engagement. In conclusion, MIJ821 showed a good safety and tolerability profile in healthy volunteers. Dissociative AEs were mild, transient, and dose‐dependent.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
- McGill University, Montreal, Québec, Canada.
- Seaview A Quotient, Miami, Florida, USA.
- Novartis Healthcare Pvt. Ltd., Hyderabad, India.
- Elminda Ltd., Herzliya, Israel.
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
ORCID profiles: Mark P Healy, Oleksandr Sverdlov, Sachin Desai
Cite
APA
Gomez-Mancilla, B., Levy, J. A., Ganesan, S., Faller, T., Issachar, G., Peremen, Z., Laufer, O., Shani-Hershkovich, R., Biliouris, K., Walker, E., Healy, M. P., Sverdlov, O., Desai, S., Ghaemi, S. N., Cha, J. H., & Shanker, Y. G. (2023). MIJ821 (onfasprodil) in healthy volunteers: First‐in‐human, randomized, placebo‐controlled study (single ascending dose and repeated intravenous dose). Clinical and Translational Science, 16(11), 2236-2252. https://doi.org/10.1111/cts.13623
Vancouver
Gomez-Mancilla B, Levy JA, Ganesan S, Faller T, Issachar G, Peremen Z, et al. MIJ821 (onfasprodil) in healthy volunteers: First‐in‐human, randomized, placebo‐controlled study (single ascending dose and repeated intravenous dose). Clinical and Translational Science. 2023;16(11):2236-2252. doi:10.1111/cts.13623
BibTeX
@article{GomezMancilla2023,
author = {Gomez-Mancilla, Baltazar and Levy, Jeffrey A and Ganesan, Subramanian and Faller, Thomas and Issachar, Gil and Peremen, Ziv and Laufer, Offir and Shani-Hershkovich, Revital and Biliouris, Kostas and Walker, Ela and Healy, Mark P and Sverdlov, Oleksandr and Desai, Sachin and Ghaemi, S Nassir and Cha, Jang-Ho and Shanker, Y Gopi},
title = {MIJ821 (onfasprodil) in healthy volunteers: First‐in‐human, randomized, placebo‐controlled study (single ascending dose and repeated intravenous dose)},
journal = {Clinical and Translational Science},
year = {2023},
volume = {16},
number = {11},
pages = {2236--2252},
doi = {10.1111/cts.13623}
}
EUVIMED